Evidence map›Paper›PMID 42853545›Full record

ArticleInternational journal of clinical oncology2026

Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy.

Ya Guo, Satoshi Saito, Kenji Makita, Tomohiro Enokida, Takashi Hiyama, Ryo Kuboki, Hirofumi Kuno, Masaki Nakamura, Yuichi Hiroshima, Hidenari Hirata and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ya GuoDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Satoshi SaitoDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Kenji MakitaDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kemaki3@east.ncc.go.jp.ORCID http://orcid.org/0000-0002-2219-6708
Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. tenokida@east.ncc.go.jp.
Takashi HiyamaDepartment of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
Ryo KubokiDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Hirofumi KunoDepartment of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
Masaki NakamuraDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Yuichi HiroshimaDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Hidenari HirataDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Masashi WakabayashiBiostatistics Division, Center for Research Administration and Support, National Cancer Center Japan Hospital East, Chiba, Japan.
Yunhao ZhangDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Nobukazu TanakaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Sadamoto ZendaDepartment of Radiation Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the association between total tumor volume reduction rate (VRR) and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) treated with paclitaxel, carboplatin, and cetuximab (PCE)-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT).

methodsPatients with LA-NPC who were planned to undergo IC-PCE followed by CCRT between September 2017 and December 2024 were included. Overall survival (OS) and progression-free survival (PFS) were calculated, and factors associated with PFS were evaluated. VRR was dichotomized based on a cutoff value derived from receiver operating characteristic curve analysis.

resultsIn total, 43 consecutive patients with LA-NPC (median age, 56 years) were included. The median follow-up time was 48 months (Interquartile Range, 34-69). The 3-year OS and PFS were 95.3% and 76.1%, respectively. A total of 12 PFS events were observed, including locoregional recurrence (n = 3), distant metastasis (n = 6), both (n = 1), and death (n = 2). In multivariable analysis adjusted for cStage (Union for International Cancer Control 9th edition), a high VRR (cutoff value, 48.6%) was identified as a significant factor associated with improved PFS (hazard ratio, 0.21; 95% confidence interval, 0.06-0.70; p = 0.01).

conclusionVRR was associated with PFS, suggesting that tumor shrinkage following IC-PCE may serve as a prognostic marker.

Indexed as

Induction chemotherapyNasopharyngeal carcinomaPCERadiotherapyTumor volume

Identifiers

PMID42853545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.